Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus Aureus

Next Previous
Trial Profile

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy for the Treatment of Adults With Bacteremia Due to Staphylococcus Aureus

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AP-SA02 (Primary) ; Antibacterials
  • Indications Bacteraemia; Staphylococcal infections
  • Focus Adverse reactions; First in man
  • Acronyms diSArm Study
  • Sponsors Armata Pharmaceuticals

Most Recent Events

  • 19 Mar 2026 According to an Armata Pharmaceuticals media release,The FDA confirmed that the safety and efficacy data from Armatas Phase 2a diSArm study are sufficient to start a Phase 3 trial.
  • 23 Feb 2026 According to an Armata Pharmaceuticals media release, company announced that the U.S. Food and Drug Administration (the FDA) has granted AP-SA02, for intravenous use as a Qualified Infectious Disease Product (QIDP) for adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus (MSSA) or methicillin resistant S. aureus (MRSA).
  • 13 Jan 2026 According to an Armata Pharmaceuticals media release, company announced the conclusion of an End-of-Phase 2 (EOP2) written response from the U.S. Food and Drug Administration (FDA) and plans to advance the Company's intravenously-administered Staphylococcus aureus bacteriophage product candidate, AP-SA02, into a Phase 3 clinical study in complicated S. aureus bacteremia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top